Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

81. Should Heparin Lock alone be recommended for the prevention of catheter thrombosis?

Should Heparin Lock alone be recommended for the prevention of catheter thrombosis? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2017 PROSPERO

82. Low molecular weight heparin versus expectant management in patients with recurrent miscarriage of unknown aetiology

Low molecular weight heparin versus expectant management in patients with recurrent miscarriage of unknown aetiology Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

83. BEXSERO - Recombinant Neisseria meningitidis serogroup B Neisseria Heparin Binding Antigen fusion proteinRecombinant Neisseria meningitidis serogroup B Neisserial Adhesin A proteinRecombinant Neisseria meningitidis serogroup B factor H binding protein

BEXSERO - Recombinant Neisseria meningitidis serogroup B Neisseria Heparin Binding Antigen fusion proteinRecombinant Neisseria meningitidis serogroup B Neisserial Adhesin A proteinRecombinant Neisseria meningitidis serogroup B factor H binding protein Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact

2017 Health Canada - Drug and Health Product Register

85. Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: a systematic review and meta-analysis

Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

86. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss [Cochrane protocol]

Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2017 PROSPERO

87. Appropriate dosing of low-molecular weight heparins for acute venous thromboembolism in obesity

Appropriate dosing of low-molecular weight heparins for acute venous thromboembolism in obesity Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

88. Direct oral anticoagulant (DOAC) versus low molecular weight heparin (LMWH) for the treatment of venous thromboembolism (VTE) in cancer patients

Direct oral anticoagulant (DOAC) versus low molecular weight heparin (LMWH) for the treatment of venous thromboembolism (VTE) in cancer patients Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

89. Does low-molecular-weight heparin improve obstetric outcome in women with recurrent pregnancy loss? A systematic review and a meta-analysis of the literature

Does low-molecular-weight heparin improve obstetric outcome in women with recurrent pregnancy loss? A systematic review and a meta-analysis of the literature Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2017 PROSPERO

90. Bivalirudin versus heparin anticoagulation in transcatheter aortic valve interventions: a systematic review and a meta-analysis

Bivalirudin versus heparin anticoagulation in transcatheter aortic valve interventions: a systematic review and a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2017 PROSPERO

91. Heparin Flushing of IV Lines

Heparin Flushing of IV Lines Rapid Review 1 Heparin flushing of IV lines Citation Centre for Clinical Effectiveness. 2017. Heparin flushing of IV lines: Rapid Review. Centre for Clinical Effectiveness, Monash Health, Melbourne, Australia. Executive Summary Background Monash Health are working on improving procedural and maintenance documentation as a result of the dramatic increase in the size of the lines service with the opening of the new Children’s Hospital. As part of this, they are re (...) - considering the use of heparin for flushing paediatric lines which is common practice around the world. Changing practice from heparin to saline at Monash Health would be a significant change in practice. Anaesthetics have engaged the Centre for Clinical Effectiveness to undertake a rapid review of current literature about the use of heparin for flushing paediatric lines. Objective The purpose of this Rapid Review was to synthesise recent evidence pertaining to the use of heparin versus saline flushing

2017 Monash Health Evidence Reviews

92. Low molecular weight heparin in one or two doses for the initial treatment of venous thromboembolic disease? Full Text available with Trip Pro

Low molecular weight heparin in one or two doses for the initial treatment of venous thromboembolic disease? The preferred dosification for low molecular weight heparins is in two doses for most patients with venous thromboembolic disease. A daily dose would make treatment simpler, less expensive and more comfortable while retaining a similar benefit and safety. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified two systematic reviews including (...) five randomized trials. We combined the evidence using meta-analysis and generated a summary of findings table following the GRADE approach. We concluded it is not clear whether the risk of recurrence differs between the two alternatives because the certainty of the evidence is very low, and that administering low molecular weight heparin in two doses might be associated to little or no difference in the risk of major bleeding and mortality.

2016 Medwave

93. Should we avoid heparin to eliminate HIT? Full Text available with Trip Pro

Should we avoid heparin to eliminate HIT? 29296689 2018 01 03 2473-9529 1 1 2016 Nov 29 Blood advances Blood Adv Should we avoid heparin to eliminate HIT? 4 10.1182/bloodadvances.2016000083 Arepally Gowthami Morey GM Division of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC. eng Journal Article 2016 11 22 United States Blood Adv 101698425 2473-9529 Conflict-of-interest disclosure: G.M.A. has received consultancy fees from Momenta and Apotex Pharmaceuticals (...) , makers of generic low-molecular-weight heparins. 2018 1 4 6 0 2016 11 22 0 0 2016 11 22 0 1 epublish 29296689 10.1182/bloodadvances.2016000083 000083 PMC5744050

2016 Blood advances

94. Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia Full Text available with Trip Pro

Polyphosphate/platelet factor 4 complexes can mediate heparin-independent platelet activation in heparin-induced thrombocytopenia Heparin-induced thrombocytopenia (HIT) is a thrombotic disorder initiated by antibodies to complexes between platelet factor 4 (PF4) and heparin. The risk of recurrent thromboembolism persists after heparin is cleared and platelet activation leading to release of PF4 has dissipated. We asked whether antigenic complexes between polyphosphates and PF4 released from (...) activated platelets might intensify or sustain the prothrombotic phenotype of HIT. PF4 forms stable, ultralarge complexes with polyphosphates of various sizes, including those released from platelets, which are recognized by the HIT-like monoclonal KKO, an immunoglobulin G2bκ monoclonal heparin/PF4 binding antibody, and by human HIT antibodies. KKO helps to protect PF4/polyphosphate complexes from degradation by phosphatases. Complement is activated when HIT antibodies bind to PF4/polyphosphate

2016 Blood advances

95. Heparin for the treatment of thrombosis in neonates. Full Text available with Trip Pro

Heparin for the treatment of thrombosis in neonates. Among pediatric patients, newborns are at highest risk of developing thromboembolism. Neonatal thromboembolic (TE) events may consist of both venous and arterial thromboses and often iatrogenic complications (eg, central catheterization). Treatment guidelines for pediatric patients with TE events most often are extrapolated from the literature regarding adults. Options for the management of neonatal TE events include expectant management (...) ; nitroglycerin ointment; thrombolytic therapy or anticoagulant therapy, or a combination of the two; and surgery. Since the 1990s, low molecular weight heparin (LMWH) has become the neonatal anticoagulant of choice. Reasons for its appeal include predictable dose response, no need for venous access, and limited monitoring requirements. The overall major complication rate is around 5%. Whether preterm infants are at increased risk is unclear. No data are available on the frequency of osteoporosis, heparin

2016 Cochrane

96. Blood transfusion and filter set requirements with citrate anticoagulation compared with heparin in renal replacement therapy Full Text available with Trip Pro

Blood transfusion and filter set requirements with citrate anticoagulation compared with heparin in renal replacement therapy 28979523 2018 11 13 1751-1437 17 4 2016 Nov Journal of the Intensive Care Society J Intensive Care Soc Blood transfusion and filter set requirements with citrate anticoagulation compared with heparin in renal replacement therapy. 357 10.1177/1751143716647395 Taylor Nick N Department of Intensive Care, Royal Surrey County Hospital, Guildford, UK. Walter Edward E

2016 Journal of the Intensive Care Society

97. Five-year outcomes following a randomized trial of femorofemoral and femoropopliteal bypass grafting with heparin-bonded or standard polytetrafluoroethylene grafts Full Text available with Trip Pro

Five-year outcomes following a randomized trial of femorofemoral and femoropopliteal bypass grafting with heparin-bonded or standard polytetrafluoroethylene grafts Cohort studies suggest superior long-term patency of luminal heparin-bonded polytetrafluoroethylene (Hb-PTFE) bypass grafts compared with standard PTFE grafts. The aim of this study was to compare the outcomes of Hb-PTFE grafts with those of standard PTFE grafts 5 years after a randomized trial.Patients with intermittent claudication

2016 EvidenceUpdates Controlled trial quality: predicted high

98. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. Full Text available with Trip Pro

Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial.  To test the optimal antithrombotic regimen in patients with acute coronary syndrome. Randomised controlled trial. Patients with acute coronary syndrome with and without ST segment elevation in 78 centres in Italy, the Netherlands, Spain, and Sweden. 7213 patients with acute coronary syndrome and planned percutaneous coronary (...) intervention: 4010 with ST segment elevation and 3203 without ST segment elevation. The primary study results in the overall population have been reported previously. Patients were randomly assigned, in an open label fashion, to one of two regimens: bivalirudin with glycoprotein IIb/IIIa inhibitors restricted to procedural complications or heparin with or without glycoprotein IIb/IIIa inhibitors. Primary endpoints were the occurrence of major adverse cardiovascular events, defined as death, myocardial

2016 BMJ Controlled trial quality: predicted high

99. Intravenous heparin during ruptured abdominal aortic aneurysmal repair. Full Text available with Trip Pro

Intravenous heparin during ruptured abdominal aortic aneurysmal repair. There have been enormous advances in the screening, diagnosis, intervention and overall prognosis of abdominal aortic aneurysms (AAAs) in the last decade, but despite these, ruptured AAAs (rAAAs) still cause around 3500 to 6000 deaths in England and Wales each year. Open repair remains standard treatment for rAAA in most centres but increasingly endovascular aneurysm repair (EVAR) is being adopted. This has a 30-day (...) postoperative mortality of 40%. This has remained static despite surgical, anaesthetic and critical care advances.One significant change to current practice for elective repairs of AAAs, as opposed to emergency repairs of rAAAs, has been the introduction of intravenous heparin. This provides a protective effect against cardiac and thrombotic disease in the postoperative period. This practice has not gained widespread acceptance for emergency repairs of rAAA even though a reduction in mortality and morbidity

2016 Cochrane

100. Increased unfractionated heparin requirements with decreasing body mass index in pregnancy Full Text available with Trip Pro

Increased unfractionated heparin requirements with decreasing body mass index in pregnancy Pregnant women receiving low-molecular-weight heparin for therapeutic anticoagulation are often converted to unfractionated heparin in anticipation of labor. We aim to characterize the impact of maternal body mass index on attainment of target anticoagulation during the conversion process.We conducted a five-year retrospective study of a pregnancy cohort converted from low-molecular-weight heparin (...) to unfractionated heparin in the third trimester. Patient demographics, anticoagulation regimens, and clinical outcomes were extracted from the medical record. Nonparametric statistical methods were used for analysis by body mass index (<30, 30-35, and >35).Thirty-one subjects were evenly distributed by body mass index (p = 0.97). Linear regression revealed an inverse correlation between patient body mass index and unfractionated heparin dose needed to achieve therapeutic anticoagulation (p = 0.04). Subjects

2016 Obstetric medicine